SELLAS Life Sciences (SLS) Change in Acquisitions & Divestments (2013)
SELLAS Life Sciences (SLS) posted quarterly Change in Acquisitions & Divestments of $2.5 million for Q4 2013, up 209.46% quarter-over-quarter from $814000.0 in Q3 2013.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Change in Acquisitions & Divestments (2013) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Change in Acquisitions & Divestments for 1 consecutive years, with $2.5 million the latest figure, recorded in Q4 2013.
- In Q4 2013, Change in Acquisitions & Divestments changed N/A year-over-year to $2.5 million; the TTM figure through Dec 2014 stood at $3.3 million (changed 0.0% YoY), while the FY2013 annual figure was $3.9 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments grew to $2.5 million in Q4 2013 per SLS's latest filing, from $814000.0 in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $2.5 million in Q4 2013 and bottomed at $814000.0 in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.65 Bn | 2.65 Bn | - |